Eli Lilly wasn't alone in reporting a big decline in sales and a drop in profits this quarter. It's the only Big Pharma today, however, whose earnings didn't disappoint analysts. Thanks to unexpectedly strong growth for the antidepressant Cymbalta, profits fell less than expected--23% to $924 million.
The market is showing its own hypersensitivity to the ongoing onslaught of generics on the the world's best-selling drugs.
The feds say the 23 suspects are tied to pharmaceutical cargo losses worth tens of millions of dollars throughout the country.
Eli Lilly ($LLY), languishing in the doldrums of its long-expected "Years YZ," has frozen the salaries of many of its staffers, including those of top management. As Pharmalot reports, the company
Pfizer ($PFE) and Eli Lilly ($LLY) are continuing the downward-sloping earnings trend that's dominated Big Pharma's fourth-quarter reports. Pfizer saw profits drop by half, while Lilly's earnings
Eli Lilly ($LLY) has long been warning about a yearslong sales trough, and those years have officially arrived. But the company says it's now projecting a deeper-than-expected drop in profits for
Alexza Pharmaceuticals may be literally going for broke as it pursues approval of its inhaled fast-acting antipsychotic drug Adasuve. The company ($ALXA) announced that it will pursue significant,
Here's one way to increase your drug sales overnight: First, buy a company. Then, raise its product prices up to 25%. That, apparently, is Teva Pharmaceutical Industries' ($TEVA) strategy for
The patent cliff is like a yurt. It has many sides. To Big Pharma, it's been a looming threat for years. To generics makers, it's a multibillion-dollar boon. To India, with its generics-heavy pharma
With sales figures showing that individual psych meds are among Big Pharma's best sellers--think Eli Lilly's ($LLY) Zyprexa, for one--it's no surprise to see the percentage of Americans using drugs